-
Rite Aid eyes closing hundreds of pharmacies
Rite Aid proposed closing nearly a fourth of its 2,100 pharmacies and declaring bankruptcy, people familiar with the matter told The Wall Street Journal in a Sept. 22 story. -
Hospital changes policies after its pharmacy director sold empty COVID-19 vaccine vials
A Chicago hospital strengthened its product disposal rules in 2021 after its pharmacy director at the time sold empty COVID-19 vaccine vials on Craigslist, CBS News reported Sept. 20. -
Penn Medicine promotes chief pharmacy officer
Philadelphia-based Penn Medicine has appointed Nishaminy Kasbekar, PharmD, as vice president and chief pharmacy officer, according to a Sept. 21 LinkedIn post. -
Florida system invests in medication adherence
Baptist Health South Florida is partnering with EveryDose, a digital health company, to digitize medication adherence processes. -
FDA panel rejects diabetes drug implant for 3rd time
An FDA panel voted 19-0 Sept. 21 to reject ITCA 650, an experimental Type 2 diabetes drug delivery product, after refusing approval twice. -
Kaiser pharmacy workers authorize strike
Kaiser Permanente pharmacy workers in Oregon and Washington plan to strike for three weeks in October, adding to the growing tally of what could be the largest healthcare strike in U.S. history. -
FDA vetoes approving 1st needle-free EpiPen, asks for more data
Before the FDA possibly approves the nation's first needle-free EpiPen product, the agency wants a San Diego-based drugmaker to conduct another study. -
Baptist Health's $40M central fill pharmacy: 5 things to know
Baptist Health, a nine-hospital system based in Louisville, Ky., is constructing a $40 million central fill pharmacy in La Grange, Ky. Here are five things to know about the project: -
Finding Solutions to U.S. Drugs Shortages in 2023 and Beyond: A Manufacturer’s Perspective
As we move closer to the end of this year, it is unfortunate to note that U.S. drug shortages are at an all-time high. Also unfortunate is that this is not a new issue. Drug shortages have been occurring in the United States for far too long. -
ADHD medication errors rose 300% since 2000, report finds
ADHD-related medication errors rose 299 percent between 2000 and 2021, according to new research published in Pediatrics on Sept. 18. -
Humira biosimilars falter in disrupting the market
Numerous Humira biosimilars are on the market after AbbVie's 20-year exclusive on the rheumatoid arthritis biologic, but they aren't fostering much competition, KFF Health News reported Sept. 19. -
FDA raises safety issue in generic organ anti-rejection drug
The FDA reduced its therapeutic equivalence rating in Accord Healthcare's tacrolimus oral capsules because of safety concerns, but the generic's approval remains, the agency said Sept. 19. -
Bausch Health CFO resigns
Tom Vadaketh, executive vice president and CFO of pharmaceutical company Bausch Health Cos., has resigned from his role and will be leaving the company effective Oct. 13. -
‘It’s never too late to start’: How a supported journey in specialty pharmacy services transforms hospital + health system finances and care delivery
Over the last few years, “doing more with less” has become a mantra for most hospitals and health systems. Many are now looking at specialty pharmacy services as a way to strengthen their financial portfolios, reduce administrative burden and deliver more patient-centered care. -
15 pharmacists in hospital C-suite, top leadership roles
Besides filling the chief pharmacy officer and pharmacy director roles, pharmacists are filling other C-suite and senior leadership jobs in hospitals. -
Ozempic, Wegovy shortages could last years
The shortages of Novo Nordisk's Ozempic and Wegovy, a Type 2 diabetes and weight loss drug, respectively, could continue for years, Forbes reported Sept. 16. -
6 drugs now in shortage
Since late August, six medications have fallen into short supply, including one cancer therapy. -
MDMA therapy reduces PTSD symptoms in phase 3 study
The potential is growing for MDMA-assisted therapy, also known as ecstasy, to be approved for treating PTSD as more research finds success. -
FDA to weigh public comments before making decision on common decongestant
Following an FDA advisory committee's determination that a common ingredient in over-the-counter cough and cold medicines is ineffective, the agency released a statement clarifying it has not yet made a final decision on the matter. -
FTC cracks down on improper drug patent filings
The Federal Trade Commission is targeting brand-name drugmakers that are improperly listing patents, which can weaken competition.
Page 47 of 50